未登录

G

Guillermo Salinas-Escudero

Hospital Infantil de México Federico Gómez

H指数:12

被引数:722

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early ethics: Exploring moral intuition and maternal Influence in preschool children

早期伦理：探究学龄前儿童的道德直觉与母性影响

IF2.6

2026-01-300

PRE

Out-of-pocket healthcare expenditures in older Mexican people based on their social security status

基于社会安全状况的墨西哥老年人自付医疗支出

Health Policy and Planning

IF3.1

2025-12-010

OAAI

Longitudinal Analysis of the Transition Between Multimorbidity and Mortality Patterns from a Syndemic Perspective

从 syndemic 视角对多病共存与死亡模式之间转变的纵向分析

ARCHIVES OF MEDICAL RESEARCH

IF3.4

2025-06-010

PRE

Editorial: Clinical, biological, and economic aspects of pediatric infections in Latin America

FRONTIERS IN PUBLIC HEALTH

IF3.4

2024-03-220

OAAI

Direct medical cost of COVID-19 in children hospitalized at a tertiary referral healthcare center in Mexico City

FRONTIERS IN PUBLIC HEALTH

IF3.4

2023-08-170

OAAI

Cost-effectiveness analysis of a hand hygiene monitoring system in a tertiary pediatric hospital in Mexico

FRONTIERS IN PUBLIC HEALTH

IF3.4

2023-03-093

OAAI

Disability-Adjusted Life Years for the COVID-19 Pandemic in the Mexican Population

FRONTIERS IN PUBLIC HEALTH

IF3.4

2021-08-1719

OAAI

A survival analysis of COVID-19 in the Mexican population (vol 20, 1616, 2020)

BMC PUBLIC HEALTH

IF3.6

2020-11-300

OAAI

A survival analysis of COVID-19 in the Mexican population

墨西哥人口中新型冠状病毒肺炎的生存分析

BMC PUBLIC HEALTH

IF3.6

2020-10-2763

OAAI

Economic impact of dengue in Mexico considering reported cases for 2012 to 2016

PLOS NEGLECTED TROPICAL DISEASES

IF3.4

2018-12-1410

OAAI

Calculation of the Average Cost per Case of Dengue Fever in Mexico Using a Micro-Costing Approach

PLOS NEGLECTED TROPICAL DISEASES

IF3.4

2016-08-086

OAAI

COST-EFFECTIVENESS OF DENOSUMAB IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS (PMO) WOMEN IN MEXICO AT HIGH RISK OF FRACTURES AND INTOLERANT TO ORAL BISPHOSPHONATES

VALUE IN HEALTH

IF6

2013-05-011

OAAI

GEMIFLOXACIN AS FIRST LINE TREATMENT FOR COMMUNITY ACQUIRED PNEUMONIA IN MEXICO: A COST-EFFECTIVENESS STUDY

VALUE IN HEALTH

IF6

2013-05-010

OAAI

ECONOMIC ASSESSMENT OF GEMIFLOXACIN FOR THE MANAGEMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS IN MEXICO

VALUE IN HEALTH

IF6

2013-05-010

OAAI

COST-UTILITY ASSESSMENT OF SIROLIMUS VERSUS TACROLIMUS FOR PRIMARY PREVENTION OF GRAFT REJECTION IN RENAL TRANSPLANT RECIPIENTS IN MEXICO

VALUE IN HEALTH

IF6

2012-06-011

OAAI

EXCHANGE RATE OR POWER PURCHASE PARITY FOR ECONOMIC EVALUATION: ESTIMATING THE COSTS OF ROTAVIRUS VACCINATION IN A SIX-YEAR PERIOD CONSIDERING DATA FROM MEXICAN CHILDREN

VALUE IN HEALTH

IF6

2011-11-010

OAAI

COST-EFFECTIVENESS ANALYSIS IN THE LONG-TERM DRUG-ELUTING STENTS VS BARE METAL STENTS IN PATIENTS WITH ISCHEMIC HEART DISEASE IN THE IMSS

VALUE IN HEALTH

IF6

2011-11-010

OAAI

Cost-Effectiveness of Treatment of Salmeterol/Fluticasone in Leukotriene Comparison with Montelukast for Childhood Asthma Control

VALUE IN HEALTH

IF6

2011-07-016

OAAI

Cost Effectiveness of Posaconazole vs. Fluconazole/Itraconazole in Prophylactic Treatment of Invasive Fungal Infections in Mexico

VALUE IN HEALTH

IF6

2011-07-015

OAAI

BUDGET IMPACT MODEL OF ABACAVIR/LAMIVUDINE FOR TREATMENT OF HIV INFECTED PATIENTS IN MEXICO

VALUE IN HEALTH

IF6

2011-05-010

OAAI